Top Page
Doseology Sciences
(MOOD)
Doseology Sciences (MOOD) vs. iShares MSCI Canada ETF (EWC)
Doseology Sciences Business Overview & Revenue Model
Doseology Sciences Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 58.33K | 98.52K | 43.09K | 16.05K | 0.00 | 0.00 | Gross Profit |
| 1.76K | -36.08K | 41.29K | -148.38K | 0.00 | 0.00 | EBIT |
| -154.33K | -377.63K | -767.13K | -1.82M | -1.56M | -431.63K | EBITDA |
| -294.94K | -319.48K | -1.78M | -1.72M | -1.47M | -431.63K | Net Income Common Stockholders |
| -280.80K | -339.85K | -1.78M | -1.94M | -1.63M | -431.63K |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 931.17K | 1.06M | 1.30M | 1.87M | 3.73M | 340.90K | Total Assets |
| 978.16K | 1.10M | 1.40M | 3.87M | 5.99M | 1.16M | Total Debt |
| 0.00 | 0.00 | 50.27K | 746.10K | 687.54K | 0.00 | Net Debt |
| -931.17K | -1.06M | -1.25M | -1.13M | -3.05M | -340.90K | Total Liabilities |
| 75.54K | 82.49K | 99.19K | 871.51K | 3.41M | 88.09K | Stockholders Equity |
| 902.62K | 1.02M | 1.30M | 3.00M | 2.58M | 1.07M |
| Cash Flow | Free Cash Flow | ||||
| -174.11K | -235.12K | -481.05K | -1.72M | -2.54M | -129.10K | Operating Cash Flow |
| -174.11K | -235.12K | -481.05K | -1.71M | -2.37M | -129.10K | Investing Cash Flow |
| 0.00 | 0.00 | 0.00 | -7.88K | -26.05K | 0.00 | Financing Cash Flow |
| -6.14K | -6.14K | -91.88K | -140.08K | 5.79M | 470.00K |
Doseology Sciences Technical Analysis
Doseology Sciences Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $5.14B | 3.23 | -45.01% | 2.85% | 17.55% | -0.69% | |
42 Neutral | C$2.14M | ― | -27.08% | ― | -27.31% | 81.88% | |
| $1.43M | ― | -58.79% | ― | ― | ― | ||
| $1.03M | ― | ― | ― | ― | |||
| $1.05M | ― | -106.50% | ― | ― | ― | ||
| $560.26K | ― | ― | ― | ― | |||
33 Underperform | C$1.03M | ― | -258.31% | ― | ― | -36.54% |
Doseology Sciences Corporate Events
Doseology Sciences Inc. has granted 155,000 incentive stock options to Chris Jackson, the newly appointed CEO and board member, with an exercise price of $0.40 per share over a five-year period. This move signifies a strategic step in strengthening the company’s leadership and potentially enhancing its market position in the biotechnology sector.
Spark’s Take on TSE:MOOD Stock
According to Spark, TipRanks’ AI Analyst, TSE:MOOD is a Neutral.
Doseology Sciences, Inc. receives an overall stock score of 43, reflecting cautious optimism tempered by ongoing financial challenges. The company’s strong cash position and strategic initiatives, like entering the U.S. market and appointing a new CEO, provide potential growth avenues. However, negative financial performance and technical indicators suggest caution. Valuation concerns due to negative earnings further weigh on the stock’s attractiveness.
To see Spark’s full report on TSE:MOOD stock, click here.
Doseology Sciences Inc. has appointed Chris Jackson as its new CEO and director, effective May 1, 2025. Jackson, known for his successful ventures in high-growth industries, is expected to lead Doseology’s strategic expansion into international markets. His experience in federally regulated sectors aligns with Doseology’s goals to scale operations and expand its distribution of oral stimulant pouches, which are formulated with natural ingredients and offer both nicotine-free and nicotine-based options. The company aims to leverage its existing partnerships and retail presence to enhance its market positioning.
Spark’s Take on TSE:MOOD Stock
According to Spark, TipRanks’ AI Analyst, TSE:MOOD is a Neutral.
Doseology Sciences, Inc. receives an overall stock score of 45, reflecting a cautious outlook. The company’s financial performance is challenged by ongoing losses and cash flow issues, but its strong cash position provides some stability. Technical analysis suggests negative market momentum, and valuation metrics indicate potential overvaluation. However, the strategic expansion into the U.S. market with new products offers a promising avenue for growth, providing a slight boost to the score.
To see Spark’s full report on TSE:MOOD stock, click here.
Doseology Sciences Inc. has announced a $1.2 million private placement to advance the commercialization of its oral stimulant product line. The funds will support the expansion of distribution across North America and Europe, engagement of top-tier industry talent, and general working capital. This strategic move is expected to enhance operational flexibility and long-term value for shareholders, positioning Doseology to scale both organically and through acquisitions.
Spark’s Take on TSE:MOOD Stock
According to Spark, TipRanks’ AI Analyst, TSE:MOOD is a Neutral.
Doseology Sciences, Inc. receives an overall stock score of 45, reflecting a cautious outlook. The company’s financial performance is challenged by ongoing losses and cash flow issues, but its strong cash position provides some stability. Technical analysis suggests negative market momentum, and valuation metrics indicate potential overvaluation. However, the strategic expansion into the U.S. market with new products offers a promising avenue for growth, providing a slight boost to the score.
To see Spark’s full report on TSE:MOOD stock, click here.
Doseology Sciences Inc. has announced the cancellation of two non-brokered strategic private placements due to recent market conditions, confirming that no securities were issued in connection with these cancellations. The company is currently reassessing the market and its strategic partnerships, indicating potential future updates that could impact its operations and industry positioning.
Spark’s Take on TSE:MOOD Stock
According to Spark, TipRanks’ AI Analyst, TSE:MOOD is a Neutral.
Doseology Sciences, Inc. receives a moderate score of 48, indicating cautious optimism. The company’s financial performance is challenged by ongoing losses and cash flow issues, though its strong cash position provides some stability. Technical analysis suggests negative market momentum, while valuation metrics indicate potential overvaluation. However, the strategic expansion into the U.S. market with new products offers a promising avenue for growth, helping to enhance the score.
To see Spark’s full report on TSE:MOOD stock, click here.
Doseology Sciences Inc. has launched Doseology USA Inc., marking its entry into the multi-billion-dollar U.S. Modern Oral Stimulant Market. This expansion aims to capitalize on the growing demand for precision-dosed, clean alternatives to traditional energy products, with a focus on caffeine and nicotine pouches that offer sustained energy without the drawbacks of caffeine crashes or sugar intake.